Teachers Retirement System of The State of Kentucky Acquires 12,219 Shares of Veracyte, Inc. (NASDAQ:VCYT)

Teachers Retirement System of The State of Kentucky increased its position in Veracyte, Inc. (NASDAQ:VCYT) by 95.6% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 24,994 shares of the biotechnology company’s stock after acquiring an additional 12,219 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Veracyte were worth $1,161,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Dark Forest Capital Management LP purchased a new stake in shares of Veracyte in the second quarter worth about $137,000. Advisor Group Holdings Inc. grew its holdings in shares of Veracyte by 100.9% during the second quarter. Advisor Group Holdings Inc. now owns 3,919 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 1,968 shares in the last quarter. NEXT Financial Group Inc raised its position in shares of Veracyte by 20.1% during the 3rd quarter. NEXT Financial Group Inc now owns 3,609 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 604 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Veracyte by 10.9% during the third quarter. PNC Financial Services Group Inc. now owns 4,338 shares of the biotechnology company’s stock worth $201,000 after purchasing an additional 425 shares during the last quarter. Finally, Vident Investment Advisory LLC bought a new position in Veracyte during the second quarter valued at approximately $216,000.

NASDAQ VCYT opened at $30.34 on Friday. Veracyte, Inc. has a 52-week low of $28.42 and a 52-week high of $86.03. The firm’s 50 day moving average price is $40.89 and its 200-day moving average price is $42.85. The company has a market cap of $2.16 billion, a PE ratio of -26.85 and a beta of 0.79.

Veracyte (NASDAQ:VCYT) last released its quarterly earnings results on Tuesday, November 9th. The biotechnology company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). Veracyte had a negative net margin of 39.14% and a negative return on equity of 3.88%. The business had revenue of $60.37 million during the quarter, compared to analysts’ expectations of $54.66 million. During the same quarter last year, the business posted ($0.08) earnings per share. As a group, equities research analysts expect that Veracyte, Inc. will post -0.49 earnings per share for the current year.

Several brokerages have commented on VCYT. Stephens initiated coverage on shares of Veracyte in a report on Friday, January 7th. They issued an “overweight” rating and a $52.00 price objective for the company. The Goldman Sachs Group assumed coverage on Veracyte in a research report on Thursday, November 18th. They set a “buy” rating and a $59.00 price objective on the stock. Raymond James boosted their price objective on shares of Veracyte from $50.00 to $62.00 and gave the company an “outperform” rating in a report on Wednesday, November 10th. Finally, William Blair reissued an “outperform” rating on shares of Veracyte in a research report on Wednesday, November 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Veracyte currently has a consensus rating of “Buy” and an average price target of $53.78.

In other Veracyte news, Director Karin Eastham sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, December 17th. The stock was sold at an average price of $45.00, for a total value of $225,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Giulia C. Kennedy sold 9,232 shares of the stock in a transaction on Monday, December 6th. The shares were sold at an average price of $36.05, for a total transaction of $332,813.60. The disclosure for this sale can be found here. Insiders have sold a total of 18,632 shares of company stock valued at $145,664,138 over the last three months. 8.30% of the stock is currently owned by insiders.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.

See Also: Book Value Per Share in Stock Trading

Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYT).

Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.